1. Howlader N, Noone AM, Krapcho M, et al (Eds). SEER Cancer Statistics Review, 1975-2017, National Cancer Institute. Bethesda, MD,, based on November 2019 SEER data submission, posted to the SEER web site, April 2020.
  2. Nishino M, Pusztaszeri MP, Pitman MB. Medullary thyroid carcinoma. In: Ali SZ, Cibas ES, eds. The Bethesda system for reporting thyroid cytopathology. 2nd ed. Cham, Switzerland: Springer International Publishing; 2018. p157-175.
  3. Santoro M, Carlomango F. Central role of RET in thyroid cancer. Cold Spring Harb Perspect Biol. 2013;5(12)a009233. doi:10.1101/cshperspect.a009233
  4. Wells SA, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25:567–610. doi:10.1089/thy.2014.0335.
  5. Moley JF, De Benedietti MK. Patterns of nodal metastases in palpable medullary thyroid carcinoma. Recommendations for extent of node dissection. Annals of Surgery, 229(6):880-888. doi:10.1097/00000658-199906000-00016
  6. Scollo C, Baudin E, Travagli J-P, et al. Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab. 2003;88(5):207-2075. doi:10.1210/jc.2002-021713
  7. Randle RW, Balentine CJ, Leverson GE, et al. Trends in the presentation, treatment, and survival of patients with medullary thyroid cancer over the past 30 years. Surgery. 2017 Jan;161(1):137-146. doi: 10.1016/j.surg.2016.04.053.
  8. Rosen JE, Lloyd RV, Brierley JD, et al. Thyroid – medullary. In: Amin MB, Edge S, Greene F, et al (Eds). AJCC cancer staging manual. 8th ed. Cham, Switzerland: Springer International Publishing; 2017. p891-901. doi 10.1007/978-3-40618-3_74. 2017.
  9. Leboulleux S, Baudin E, Travagli J-P, Schlumberger M. Medullary thyroid carcinoma. Clinical Endocrinology. 2004;61(3):299-310. doi:10.1111/j.1365-2265.2004.02037.x.